Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Oct 1;75(10):1198-1205.
doi: 10.1001/jamaneurol.2018.1578.

Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline: A Study Using Optical Coherence Tomography

Affiliations
Multicenter Study

Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline: A Study Using Optical Coherence Tomography

Fang Ko et al. JAMA Neurol. .

Abstract

Importance: Identifing potential screening tests for future cognitive decline is a priority for developing treatments for and the prevention of dementia.

Objective: To examine the potential of retinal nerve fiber layer (RNFL) thickness measurement in identifying those at greater risk of cognitive decline in a large community cohort of healthy people.

Design, setting, and participants: UK Biobank is a prospective, multicenter, community-based study of UK residents aged 40 to 69 years at enrollment who underwent baseline retinal optical coherence tomography imaging, a physical examination, and a questionnaire. The pilot study phase was conducted from March 2006 to June 2006, and the main cohort underwent examination for baseline measures from April 2007 to October 2010. Four basic cognitive tests were performed at baseline, which were then repeated in a subset of participants approximately 3 years later. We analyzed eyes with high-quality optical coherence tomography images, excluding those with eye disease or vision loss, a history of ocular or neurological disease, or diabetes. We explored associations between RNFL thickness and cognitive function using multivariable logistic regression modeling to control for demographic as well as physiologic and ocular variation.

Main outcomes and measures: Odds ratios (ORs) for cognitive performance in the lowest fifth percentile in at least 2 of 4 cognitive tests at baseline, or worsening results on at least 1 cognitive test at follow-up. These analyses were adjusted for age, sex, race/ethnicity, height, refraction, intraocular pressure, education, and socioeconomic status.

Results: A total of 32 038 people were included at baseline testing, for whom the mean age was 56.0 years and of whom 17 172 (53.6%) were women. A thinner RNFL was associated with worse cognitive performance on baseline assessment. A multivariable regression controlling for potential confounders showed that those in the thinnest quintile of RNFL were 11% more likely to fail at least 1 cognitive test (95% CI, 2.0%-2.1%; P = .01). Follow-up cognitive tests were performed for 1251 participants (3.9%). Participants with an RNFL thickness in the 2 thinnest quintiles were almost twice as likely to have at least 1 test score be worse at follow-up cognitive testing (quintile 1: OR, 1.92; 95% CI, 1.29-2.85; P < .001; quintile 2: OR, 2.08; 95% CI, 1.40-3.08; P < .001).

Conclusions and relevance: A thinner RNFL is associated with worse cognitive function in individuals without a neurodegenerative disease as well as greater likelihood of future cognitive decline. This preclinical observation has implications for future research, prevention, and treatment of dementia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ko receives grant support from University College of London (UCL). Ms Muthy receives personal fees from UCL. Prof Sudlow is chief scientist at UK Biobank. Prof Rees receives grant support from Wellcome Trust and personal fees from Google DeepMind. Dr Yang and Mr Reisman are employed by Topcon Medical Systems Inc. Dr Keane receives personal fees from Allergan, Topcon, Heidelberg Engineering, Haag-Streit, Novartis, Bayer, Optos, and DeepMind as well as grant support from a Clinician Scientist award (CS-2014-14-023) from the National Institute for Health Research (NIHR). Dr Petzold receives personal fees and grant support from Novartis and is a member of the steering committee of the Optical Coherence Tomography Trial in Multiple Sclerosis (OCTiMS), which is sponsored by Novartis and for which he has not received honoraria Prof Foster receives personal fees from Allergan, Carl Zeiss, Google/DeepMind, and Santen; grant support from Alcon, and support from the Richard Desmond Charitable Trust, via Fight for Sight, London. Dr Patel receives grant support from Topcon Medical Systems Inc. Prof Khaw is supported in part by the Helen Hamlyn Trust. No other disclosures are reported.

Figures

Figure 1.
Figure 1.. Proportion of UK Biobank Participants Exhibiting a Cognitive Deficit at Baseline Testing
The cross-sectional data showing the proportion (with 95% CIs) of 32 038 UK Biobank participants with a cognitive deficit (a failing score on 2 or more of 4 tests), according to quintile of retinal nerve fiber layer (RNFL) thickness measured in the outer nasal retinal subfield by optical coherence tomography.
Figure 2.
Figure 2.. Proportion of UK Biobank Participants Exhibiting a Decline in Cognitive Function on Repeat Assessment
The number of cognitive tests with worse scores on follow-up testing was significantly associated with baseline retional nerve fiber layer (RNFL) thickness. The regression coefficient was 1.2 μm per test failed (P < .001). After controlling for potential confounders, including age, sex, race/ethnicity, Townsend deprivation index, height, refraction, and intraocular pressure, the regression coefficient was 1.1 μm per test failed (P < .001).

Comment in

Similar articles

Cited by

References

    1. GBD 2015 Neurological Disorders Collaborator Group Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877-897. doi:10.1016/S1474-4422(17)30299-5 - DOI - PMC - PubMed
    1. Saint Martin M, Sforza E, Barthélémy JC, et al. ; PROOF group study . Long-lasting active lifestyle and successful cognitive aging in a healthy elderly population: the PROOF cohort. Rev Neurol (Paris). 2017;173(10):637-644. doi:10.1016/j.neurol.2017.05.009 - DOI - PubMed
    1. Mormino EC, Betensky RA, Hedden T, et al. . Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71(11):1379-1385. doi:10.1001/jamaneurol.2014.2031 - DOI - PMC - PubMed
    1. Wirth M, Villeneuve S, Haase CM, et al. . Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70(12):1512-1519. - PMC - PubMed
    1. Bateman RJ, Xiong C, Benzinger TL, et al. ; Dominantly Inherited Alzheimer Network . Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753 - DOI - PMC - PubMed

Publication types